Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
As part of their well-established partnership, the United Nations Institute for Training and Research (UNITAR) and Takeda (TSE:4502/NYSE:TAK), a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries’ healthcare systems to meet patients’ need for plasma and plasma-derived therapies. The initiative will draw on UNITAR’s expertise in training and education toward the development of innovative solutions to global challenges and Takeda’s deep knowledge of rare disease and the plasma ecosystem.
Global demand for plasma has greatly increased over the past 20 years and is continuing to grow due to increasing numbers of patients with rare diseases being diagnosed, as well as higher standards of care and broader access to treatment globally. This demand for life-changing and life-sustaining plasma-derived therapies far exceeds available supply, resulting in more people around the world struggling to access the treatments they need, especially in low- and middle-income countries.
The overall goal of this initiative is to create a neutral, UN-based platform that will bring together experts, policymakers, patient organizations, academia, civil society and the private sector. Through increasing awareness, building partnerships and facilitating access to the latest scientific knowledge and best practices, this platform aims to support countries in finding their own tailored solutions on how to improve the quality of life and life expectancy of patients who rely on plasma-derived therapies. The project will also focus on complementing and finding synergies with other existing initiatives to improve plasma ecosystems and increase patient access to care.
The importance of plasma-derived therapies is affirmed by their inclusion in the WHO Model List of Essential Medicines1, emphasizing their significance for the healthcare system and the need to facilitate access to these products in all countries. Similarly, an increasing number of countries acknowledges the need for – and interest in – strengthening the resilience of their healthcare systems in the field of plasma supply. Pending official confirmation, the pilot phase of the current initiative will be implemented in collaboration with two countries, whose forward-thinking participation in this program to bolster their countries’ health infrastructure around plasma and the patients plasma-derived therapies can help will serve as a pathfinder for potential expansion of the project in the future.
UNITAR will serve as a coordinator of the project, hosting the platform as a collaborative framework for stakeholders to meet, lead informed discussion and lay the groundwork for future collaboration.
"Availability of life-saving and life-sustaining plasma-derived therapies can be a matter of life or death. As part of our mandate within the United Nations System, we will work hand-in-hand with Takeda to build capacity, increase awareness, enhance partnerships and facilitate access to the latest scientific knowledge and best practices in this field,” said Nikhil Seth, UN Assistant Secretary-General and Executive Director of UNITAR. “I am glad to see the partnership between UNITAR and Takeda growing. It can serve as a powerful example of how public-private partnerships can contribute to the goals of the Agenda 2030, and address some of the urgent global challenges, such as ensuring access to health, reducing inequalities, or improving the quality of technical education.”
As a founding sponsor, Takeda will serve as one of the knowledge partners providing plasma expertise, funding and project support.
“We are thrilled to extend Takeda’s established partnership with UNITAR through this new joint initiative to help address the challenges of global plasma supply and provide more plasma-derived therapies to patients who need them,” said Giles Platford, President of Takeda’s Plasma-Derived Therapies Business Unit. “Innovative partnerships that bring together a broad bench of multi-area stakeholders are crucial in strengthening healthcare infrastructure and policy to enable broader access to treatments for people around the world with rare and complex chronic disease.”
The United Nations Institute for Training and Research (UNITAR) provides innovative learning solutions to individuals, organizations and institutions to enhance global decision-making and support country-level action for shaping a better future. With a strategy fully focused on achieving the Sustainable Development Goals, UNITAR supports Governments to implement the 2030 Agenda. Our work is aligned with the 2030 Agenda and is structured around four thematic pillars: Peace, People, Planet, Prosperity, and in addition, the cross-cutting nature of our work on strengthening multilateral diplomacy, promoting the 2030 Agenda, and delivering applied research solutions through technology and data contributes to delivering our products and services in all pillars. Our mission is to develop the individual, institutional and organizational capacities of countries and other United Nations stakeholders through high-quality learning solutions and related knowledge products and services to enhance decision making and to support country-level action for overcoming global challenges. For more information, please visit https://www.unitar.org.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
For the purposes of this notice, “release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Enters into Antibody Agreement with ADC Therapeutics28.11.2022 15:47:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales. Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogen’s Project Integrum (also called RenMiceTM HiTS
Medimaps Group Appoints Meinhard F. Schmidt as Board Chairman; Adds Anne Le Grand and Five Additional Board Members28.11.2022 15:15:00 CET | Press release
Medimaps Group (www.medimapsgroup.com), a Swiss/Global med-tech company specializing in image processing software for assessing bone health, today announced new appointments to its Board of Directors, effective immediately. Meinhard F. Schmidt, an international MedTech/BioTech and Digital Health executive with 25+ years of experience, has been named Board Chairman; and Anne Le Grand,an accomplished healthcare executive and consultant with 30+ years in the global healthcare technology industry, has joined as an independent board member. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005146/en/ Medimaps Group Announces Board Members: Meinhard F. Schmidt as Board Chairman, and Anne Le Grand Plus Five Other Members and One Strategic Advisor. (Photo: Business Wire) Five additional board members and one board advisor have also been named, bolstering Medimaps investment and clinical policy expertise. Visit Medimaps website fo
Viz.ai Appoints Radiology Advisory Board to Advance Innovation28.11.2022 14:00:00 CET | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Radiology Advisory Board to assist Viz.ai in the development of strategy and products to support radiologists and patients. The Board consists of 14 leading healthcare experts with diverse experience and roles in radiology. “I am honored to co-chair the Radiology Advisory Board and excited about Viz.ai’s commitment to customers and patients to invest in innovation that increases access to life-saving therapies,” said Kevin Abrams, MD, medical director of neuroradiology and MRI and chief of radiology at Baptist Hospital in Miami. “I am looking forward to the rich dialogue to be discussed in our inaugural meeting, exploring future ideas.” “I’m looking forward to working with these esteemed board members to help shape Viz.ai’s Radiology Program through patient-centric vision, passion, and insights,” said Suzie Bash, MD, Co-Chair of the Viz.ai Radiology Advisory Board a
Viz.ai Launches AI-powered Viz™ Radiology Suite28.11.2022 14:00:00 CET | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the introduction of an AI-powered radiology suite, specifically designed to alert the radiologist in their workflow of suspected diseases, prioritize worklists, and connect care teams in real-time. The Viz™ Radiology Suite integrates into the picture archiving and communication systems (PACS) of healthcare organizations to securely facilitate access to imaging data across departments and streamline patient diagnosis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005172/en/ Screen shots of Viz Radiology Suite including worklist and PACS integration (Graphic: Business Wire) “With an increasing demand for imaging studies and a global shortage of radiologists, technologies that can be easily integrated into radiology workflows to enhance efficiency and streamline patient care are sorely needed,” said Allan Brook, M.D., FA
Wipro Launches AWS Skills Guild Program: Step Up28.11.2022 13:55:00 CET | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, announced the launch of its new Skills Guild with Amazon Web Services (AWS) at AWS re:Invent 2022. AWS Skills Guild is a comprehensive enablement program for large enterprises to build cloud skills through integrated delivery of AWS learning opportunities. Wipro Step Up will use the AWS Skills Guild framework to transform the way employees engage with clients on their AWS Cloud journeys. “As the world continues to evolve and cloud becomes the foundation for business success, we are doubling down on our strategic partnerships to advance our clients’ business goals and help them drive new competitive advantage in a rapidly changing world,” said Jason Eichenholz, Senior Vice President and Global Head of Ecosystems and Partnerships, Wipro Limited. “Our Skills Guild builds on our existing cloud capabilities and deepens our AWS competencies to help clients drive accelerated ROI from AWS
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom